Arrowhead Pharmaceuticals (ARWR) FY2026 results: revenue $451 million, down 45.6% on the year
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $451 million for fiscal 2026, the year ended 30 September 2026, down 45.6% on the year before. Net income was -$724 million, and diluted earnings per share $-5.11. The figures are the company's own, from the 10-K it filed with the SEC on 12 November 2026.
Revenue
$451 million
-45.6% on the year
FY2019FY2026
Operating margin
-156.9%
11.9% a year earlier
FY2019FY2026
Net income
-$724 million
FY2019FY2026
Diluted EPS
-$5.11
FY2019FY2026
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2026
FY2025
FY2024
On the year
Last 8 years
Operating cash flow
-272
180
-463
Capital expenditure
12.0
22.7
141
-47.1%
Free cash flow
-284
157
-604
Free cash flow margin
-63.0%
18.9%
-17018.3%
Cash from investing
-670
-129
-420
Cash from financing
777
74.0
871
+949.7%
Depreciation and amortisation
24.7
22.2
16.9
+11.3%
Share-based compensation
68.1
63.4
74.0
+7.5%
Diluted shares, weighted
142m
134m
120m
+5.9%
Shares outstanding at period end
141m
136m
124m
+4.1%
Balance sheet
$ million
FY2026
FY2025
FY2024
On the year
Last 8 years
Shareholders' equity
50.3
466
185
-89.2%
Non-controlling interest
0.2
37.4
5.6
-99.5%
Debt
879
255
393
+244.8%
Operating lease liabilities
116
104
111
+11.2%
Other liabilities
693
523
445
+32.5%
Total liabilities and equity
1,738
1,385
1,140
+25.5%
Fixed assets
371
383
386
-2.9%
Intangible assets
5.2
6.9
8.6
-24.8%
Investments
1,130
693
578
+63.1%
Cash and equivalents
62.7
227
103
-72.3%
Receivables
9.9
6.8
0.0
+45.6%
Inventory
9.1
0.0
n/a
Other assets
150
69.7
64.2
+114.8%
Total assets
1,738
1,385
1,140
+25.5%
10-K for the year ended 30 September 2026, filed 12 November 2026: the filing.